Publication Name	World Journal of Hepatology
Manuscript ID	18457
Country	Japan

Received	2015-04-21 08:43
Peer-Review Started	2015-04-22 08:54
To Make the First Decision	2015-07-17 17:53
Return for Revision	2015-07-25 15:45
Revised	2015-07-27 20:13
Second Decision	2015-09-02 15:38
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2015-09-08 15:59
Articles in Press	2015-09-08 15:59
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-09-14 09:15
Publish the Manuscript Online	2015-09-23 12:28

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Hepatitis B virus reactivation with a rituximab-containing regimen
Manuscript Source	Invited Manuscript
All Author List	Yutaka Tsutsumi, Yoshiya Yamamoto, Shinichi Ito, Hiroyuki Ohigashi, Souichi Shiratori, Hirohito Naruse and Takanori Teshima
Funding Agency and Grant Number
Corresponding Author	Yutaka Tsutsumi, MD, PhD, Department of Hematology, Hakodate Municipal Hospital, 1-10-1, Minato-cho, Hakodate 041-8680, Japan. yutsutsu@shore.ocn.ne.jp
Key Words	Rituximab; Hepatitis B virus; Reactivation; Nucleoside analog; Non-Hodgkin’s lymphoma
Core Tip	For preventive measures against hepatitis B virus (HBV) reactivation during rituximab treatment, hepatitis B surface (HBs) antigen positive and HBc antibody positive/HBs antibody negative patients are subject to prophylactic treatment with nucleoside analogs. During rituximab treatment, the HBV-DNA levels of patients who are HBc antibody positive (HBs antibody positive or negative) are ideally monitored with PCR once a month. If the PCR results are positive, the administration of nucleoside analogs is initiated. However, since monitoring HBV-DNA levels is expensive, it might be preferable to follow the HBs antibodies instead. Due to wide differences in the insurance situa-tions in each country, including the follow-up intervals, further research must determine ideal follow-up intervals. However, no standard exists for the timing of this treatment’s termination. For HBs antigen negative patients who also receive nucleoside analog treatment, it will be necessary in the future to evaluate the possibility of switching to a vaccine when a patient becomes HBs antibody positive.
Publish Date	2015-09-23 12:28
Citation	Tsutsumi Y, Yamamoto Y, Ito S, Ohigashi H, Shiratori S, Naruse H, Teshima T. Hepatitis B virus reactivation with a rituximab-containing regimen. World J Hepatol 2015; 7(21): 2344-2351
URL	http://www.wjgnet.com/1948-5182/full/v7/i21/2344.htm
DOI	http://dx.doi.org/10.4254/wjh.v7.i21.2344

Full Article (PDF)	WJH-7-2344.pdf
Full Article (Word)	WJH-7-2344.doc
Manuscript File	18457-Review.docx
Answering Reviewers	18457-Answering reviewers.pdf
Audio Core Tip	18457-Audio core tip.wav
Conflict-of-Interest Disclosure Form	18457-Conflict-of-interest statement.pdf
Copyright License Agreement	18457-Copyright assignment.pdf
Peer-review Report	18457-Peer-review(s).pdf
Scientific Misconduct Check	18457-Scientific misconduct check.pdf
Scientific Editor Work List	18457-Scientific editor work list.pdf